6-methyl-2-(3-piperidin-1-ylpropyl)-4-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-1H-pyrrolo[3,2-c]pyridine
C29H41N5 — CID 118152921
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-methyl-2-(3-piperidin-1-ylpropyl)-4-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-1H-pyrrolo[3,2-c]pyridine
6-methyl-2-(3-piperidin-1-ylpropyl)-4-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-1H-pyrrolo[3,2-c]pyridine (PubChem CID 118152921) has the molecular formula C29H41N5 and a molecular weight of 459.68 g/mol. Its IUPAC name is 6-methyl-2-(3-piperidin-1-ylpropyl)-4-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-1H-pyrrolo[3,2-c]pyridine.
Molecular Properties
| Compound Name | 6-methyl-2-(3-piperidin-1-ylpropyl)-4-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-1H-pyrrolo[3,2-c]pyridine |
|---|---|
| PubChem CID | 118152921 |
| Molecular Formula | C29H41N5 |
| Molecular Weight | 459.68 g/mol |
| Exact Mass | 459.34 |
| IUPAC Name | 6-methyl-2-(3-piperidin-1-ylpropyl)-4-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-1H-pyrrolo[3,2-c]pyridine |
| SMILES | Cc1cc2[nH]c(CCCN3CCCCC3)cc2c(-c2ccc(N3CCN(C(C)C)CC3)cc2)n1 |
| InChI | InChI=1S/C29H41N5/c1-22(2)33-16-18-34(19-17-33)26-11-9-24(10-12-26)29-27-21-25(31-28(27)20-23(3)30-29)8-7-15-32-13-5-4-6-14-32/h9-12,20-22,31H,4-8,13-19H2,1-3H3 |
| InChIKey | MSKRATBCARJBLQ-UHFFFAOYSA-N |
| XLogP | 5.49 |
| TPSA | 38.40 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 459.68 |
| LogP ≤ 5 | 5.49 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118152921 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.